美国联邦贸易委员会迫使快递公司对胰岛素定价进行全面改革, 终止回扣, 提高透明度. FTC forces Express Scripts to overhaul insulin pricing, ending kickbacks and boosting transparency.

公平贸易委员会就其胰岛素定价做法与Express Scripts达成了具有里程碑意义的解决方案,要求PBM终止对高成本药物的偏好,转向基于净价格的费用分摊,取消受回扣驱动的模式,并提高透明度。 The FTC has reached a landmark settlement with Express Scripts over its insulin pricing practices, requiring the PBM to end preferences for high-cost drugs, shift to net price-based cost-sharing, dismantle rebate-driven models, and improve transparency. 这项交易是更广泛的监管监督的一部分,它反映了劳工部一项新的规则,即授权个人银行披露所有补偿,包括回扣和分散定价,在合同前向赞助者进行规划。 The deal, part of broader regulatory scrutiny, mirrors a new Department of Labor rule mandating PBMs to disclose all compensation, including rebates and spread pricing, to plan sponsors before contracts. 这些行动旨在遏制隐性收费、减少利益冲突和降低消费者的药物成本,这反映了政府加紧努力提高药品供应链的透明度和竞争。 These moves aim to curb hidden fees, reduce conflicts of interest, and lower drug costs for consumers, reflecting intensified government efforts to increase transparency and competition in the pharmaceutical supply chain.